Amgen’s Imdelltra Cut Lung Cancer Deaths by 58%. Is It Already in the Stock?
Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced lung cancer death risk by 58% in a trial. Amgen reports median survival of 21.1 months vs. 12.7 months with Imfinzi alone. Imdelltra sales grew to $288M in Q2 2026, but represents only 2.9% of Amgen's total revenue. Analysts expect Amgen's revenue to grow 4% annually through 2030.
How this was made
The 30-second read
Why it matters
The trial's mortality benefit could reshape Amgen's oncology pipeline valuation and drive near‑term share price appreciation.
Market read
First‑time disclosure of a major Phase 3 oncology result; likely catalyst for Amgen and sector.
What to watch
Safety signals (20.9% grade 3+ events) and modest market size (~35‑40k patients) may limit revenue upside.
Background
Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, targets extensive‑stage small‑cell lung cancer, a high‑unmet‑need area.
Ticker impact
Amgen disclosed Phase 3 DeLLphi-305 trial results showing a 58% reduction in death risk for extensive-stage SCLC, the first public release of these data.
upward pressure as the market incorporates the survival benefit
The 58% mortality reduction is a material clinical breakthrough; analysts will upgrade forecasts and investors may add exposure ahead of potential FDA filing.
Market effects
Oncology and biotech sectors may see broader rally on the perception of a new effective SCLC therapy.
U.S. biotech indices likely gain; limited immediate effect on other regions.
Potential global interest as Amgen may seek worldwide approvals, influencing global biotech sentiment.
Counterpoint
If the trial data fail to translate into regulatory approval or commercial uptake, the stock could face disappointment after an initial bump.
Key entities
- CompanyAmgen
US‑listed biotech firm reporting the trial results.
